Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
RG Advertising
TeraRecon

Proton Therapy for Prostate Cancer Patients Offers Long-Term Patient Survival with Optimal Quality of Life

By Medimaging International staff writers
Posted on 26 Feb 2014
Image: Patient preparing to undergo proton therapy (Photo courtesy of the University of Florida Proton Therapy Institute).
Image: Patient preparing to undergo proton therapy (Photo courtesy of the University of Florida Proton Therapy Institute).
Five years after having proton therapy for the treatment of early- and intermediate-risk prostate cancer, 99% of men are cancer-free and with excellent quality of life, according to new findings. Three-quarters of those patients with high-risk prostate cancer are also disease-free.

The University of Florida (UF) Proton Therapy Institute (Jacksonville, USA) study, published in the March 1, 2014, issue of the International Journal of Radiation Oncology Biology Physics, adds to the body of evidence pointing to an important role for proton therapy in the effective treatment of prostate cancer, according to Nancy P. Mendenhall, MD, lead author and medical director of the UF Proton Therapy Institute.

“These proton therapy results compare very favorably with IMRT [intensity-modulated radiation therapy] results, particularly for intermediate risk-disease, where disease control rates of 70%–85% are typical,” said Dr. Mendenhall, the associate chair of the UF College of Medicine department of radiation oncology. IMRT is a type of radiation that uses photons, or X-rays, to deliver radiation. Proton therapy utilizes protons, particles of an atom, to deliver radiation.

The study monitored 211 patients who participated in prospective Institutional Review-Board approved trials. In each track, patients were administered proton therapy over an eight-week period, a shorter interval than typical with IMRT, which may last nine to nine-and-a-half weeks. Researchers used standardized data-collecting techniques for both physician-reported and patient-reported outcomes.

The findings revealed cancer-free survival rates at five years for low-, intermediate-, and high-risk patients are 99%, 99%, and 76%, respectively, whereas overall survival rates are 93%, 88%, and 90%. Furthermore, the serious gastrointestinal and urologic complication rate is low, at 1.4% and 5.3%, respectively, for all patients. Patients also reported good outcomes in relation to both urologic and bowel functions.

Related Links:

University of Florida Proton Therapy Institute 



Channels

MRI

view channel
Image: Construction Workers Building CUBRIC (Photo courtesy of Cardiff University).

New Brain Research Imaging Center Under Construction in Cardiff University

Cardiff University (Cardiff, UK) has begun building an advanced MR imaging technology center, with the help of Siemens Healthcare (Erlangen, Germany). The center will use the latest brain imaging and brain... Read more

General/Advanced Imaging

view channel
Image: Measuring the Magnetic Activity in the Brain of a Child, Using a MEG machine. (Photo courtesy of Children\'s Hospital of Philadelphia).

Study Suggests Language Delay Linked to Chromosome Deletion in Children with Neurological Disorders

A study found that children with neuro-developmental problems born with DNA duplications or deletions on part of chromosome 16, show measurable delays in their ability to process sound and language.... Read more

Imaging IT

view channel

European Governments Adopting Country-Specific Electronic Health Record Implementation Models

Frost & Sullivan (Mountain View, CA, USA) has released a new analysis of the Electronic Health Records (EHR) market in Europe. The study analyzes the hospital and ambulatory EHR market. According to the study, the market earned revenues of USD 2.74 billion in 2014, and is expected to reach USD 3.69 billion in 2020.... Read more

Industry News

view channel

Long-Term Contract for Telehealth Services Awarded by German Health Insurance Company

Almeda (Munich, Germany), a subsidiary of SHL Telemedicine (Tel Aviv, Israel), has won a public tender for an 8-year contract worth EUR 16–20 million offered by Barmer GEK (Wuppertal, Germany), a health insurance company, to provide telehealth services to clients insured at Barmer. Barmer GEK was already a long-term client... Read more
 

Events

05 Mar 2015 - 08 Mar 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.